Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer

Table 1 Effect of Zt/g4-Directed DM1 Delivery on Cell Cycle Changes by human breast and NSCLC Cell Lines^a

Cancer cell lines	Changes of cell cycles after Zt/g4-DM1 treatment (%)
	G0/G1 phase				S phase				G2/M phase
	0 h	6 h	12 h	24 h	0 h	6 h	12 h	24 h	0 h	6 h	12 h	24 h
MCF7	50.49	51.56	47.59	42.19	23.95	23.75	25.08	26.78	25.57	24.69	27.33	31.03
DU4475	51.14	40.92	23.22	10.13	10.42	18.24	16.37	13.5	38.42	40.91	60.40	76.37
MDA-MB-231	48.38	35.40	17.56	7.23	17.52	25.21	21.90	10.05	34.24	39.50	60.63	82.62
T-47D	64.71	62.81	35.63	14.74	7.06	10.15	28.61	10.29	28.24	27.04	35.76	74.97
H1993	56.40	54.55	53.28	50.17	16.00	16.53	18.03	15.87	27.60	28.93	28.69	33.95
H2228	63.56	58.23	48.85	27.21	13.98	13.92	12.95	8.16	22.46	27.85	38.20	64.63
H358	46.60	29.22	28.13	18.69	14.63	17.81	18.23	14.65	38.78	52.97	53.65	66.67

^aBreast and NSCLC cell lines at 1 × 106 cells per culture dish in DMEM with 10 % FBS were treated at 37 °C for 0, 6, 12 and 24 h with 5 μg/ml of Zt/g4-DM1. After treatment, cells were labeled with propidium iodide and then analyzed by an Accuri Flow Cytometer. Cell cycle changes were determined by measuring DNA contents as previously described (25)

ISSN: 1756-9966